Valproic acid - Revision history

Lazy at 08:17, 18 January 2025

2025-01-18T08:17:40Z

← Older revision		Revision as of 01:17, 18 January 2025
Line 14:		Line 14:
	\|toxicity_level=3		\|toxicity_level=3
	\|toxicity_explanation=Valproic Acid/Sodium Valproate (Depakote) is a drug that has been used for epilepsy and is being investigated for the treatment of glioblastoma. It has risks associated with use, including potential liver toxicity, changes in levels of liver enzymes, increased concentration of chemotherapy in the body, plus side effects like sleepiness and constipation. These side effects and risks, while significant, are not the most severe among cancer treatments, thus rating it a 3 out of 5 for toxicity level.		\|toxicity_explanation=Valproic Acid/Sodium Valproate (Depakote) is a drug that has been used for epilepsy and is being investigated for the treatment of glioblastoma. It has risks associated with use, including potential liver toxicity, changes in levels of liver enzymes, increased concentration of chemotherapy in the body, plus side effects like sleepiness and constipation. These side effects and risks, while significant, are not the most severe among cancer treatments, thus rating it a 3 out of 5 for toxicity level.
	}}		\|overview=Valproic Acid/Sodium Valproate (Depakote) is an FDA-approved anti-epileptic drug that is being explored for investigational use in glioblastoma due to its HDAC inhibition properties, showing potential to improve median survival rates. Although retrospective studies suggest benefits, including extended survival and progression-free survival, the need for further clinical trials is emphasized due to contested results and associated risks of liver toxicity and other side effects.}}

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:25:19Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:25, 12 November 2024
Line 10:		Line 10:
	\|usefulness_rating=3		\|usefulness_rating=3
	\|notes=Valproic acid, an anti-epileptic drug and HDAC inhibitor, has shown potential to improve clinical outcomes in glioblastoma patients. While initial retrospective analyses suggest benefits, particularly in extending median survival and PFS, the results are contested. The debate continues, emphasizing the need for rigorously designed clinical trials to conclusively determine Valproic acid's efficacy in glioblastoma treatment.		\|notes=Valproic acid, an anti-epileptic drug and HDAC inhibitor, has shown potential to improve clinical outcomes in glioblastoma patients. While initial retrospective analyses suggest benefits, particularly in extending median survival and PFS, the results are contested. The debate continues, emphasizing the need for rigorously designed clinical trials to conclusively determine Valproic acid's efficacy in glioblastoma treatment.
	\|~~category~~=Repurposed Drugs		\|treatment_category=Repurposed Drugs
	\|links=		\|links=
	\|toxicity_level=3		\|toxicity_level=3
	\|toxicity_explanation=Valproic Acid/Sodium Valproate (Depakote) is a drug that has been used for epilepsy and is being investigated for the treatment of glioblastoma. It has risks associated with use, including potential liver toxicity, changes in levels of liver enzymes, increased concentration of chemotherapy in the body, plus side effects like sleepiness and constipation. These side effects and risks, while significant, are not the most severe among cancer treatments, thus rating it a 3 out of 5 for toxicity level.		\|toxicity_explanation=Valproic Acid/Sodium Valproate (Depakote) is a drug that has been used for epilepsy and is being investigated for the treatment of glioblastoma. It has risks associated with use, including potential liver toxicity, changes in levels of liver enzymes, increased concentration of chemotherapy in the body, plus side effects like sleepiness and constipation. These side effects and risks, while significant, are not the most severe among cancer treatments, thus rating it a 3 out of 5 for toxicity level.
	}}		}}

Lazy at 16:53, 27 March 2024

2024-03-27T16:53:26Z

← Older revision		Revision as of 09:53, 27 March 2024
Line 12:		Line 12:
	\|category=Repurposed Drugs		\|category=Repurposed Drugs
	\|links=		\|links=
			\|toxicity_level=3
			\|toxicity_explanation=Valproic Acid/Sodium Valproate (Depakote) is a drug that has been used for epilepsy and is being investigated for the treatment of glioblastoma. It has risks associated with use, including potential liver toxicity, changes in levels of liver enzymes, increased concentration of chemotherapy in the body, plus side effects like sleepiness and constipation. These side effects and risks, while significant, are not the most severe among cancer treatments, thus rating it a 3 out of 5 for toxicity level.
	}}		}}

Lazy at 13:03, 20 March 2024

2024-03-20T13:03:44Z

← Older revision		Revision as of 06:03, 20 March 2024
Line 10:		Line 10:
	\|usefulness_rating=3		\|usefulness_rating=3
	\|notes=Valproic acid, an anti-epileptic drug and HDAC inhibitor, has shown potential to improve clinical outcomes in glioblastoma patients. While initial retrospective analyses suggest benefits, particularly in extending median survival and PFS, the results are contested. The debate continues, emphasizing the need for rigorously designed clinical trials to conclusively determine Valproic acid's efficacy in glioblastoma treatment.		\|notes=Valproic acid, an anti-epileptic drug and HDAC inhibitor, has shown potential to improve clinical outcomes in glioblastoma patients. While initial retrospective analyses suggest benefits, particularly in extending median survival and PFS, the results are contested. The debate continues, emphasizing the need for rigorously designed clinical trials to conclusively determine Valproic acid's efficacy in glioblastoma treatment.
	\|category=~~Investigational~~ Drugs		\|category=Repurposed Drugs
	\|links=		\|links=
	}}		}}

Lazy: Created page with "{{TreatmentInfo |drug_name=Valproic Acid/Sodium Valproate (Depakote) |FDA_approval=Yes (for epilepsy) |used_for=Investigational use in glioblastoma for its HDAC inhibition properties |clinical_trial_phase=Retrospective studies and a prospective phase II trial |common_side_effects=Liver enzyme non-induction, potential increase in chemotherapy concentration, somnolence, constipation, potential liver toxicity |OS_without=Median survival with enzyme-inducing anticonvulsants:..."

2024-03-20T13:01:15Z

Created page with "{{TreatmentInfo |drug_name=Valproic Acid/Sodium Valproate (Depakote) |FDA_approval=Yes (for epilepsy) |used_for=Investigational use in glioblastoma for its HDAC inhibition properties |clinical_trial_phase=Retrospective studies and a prospective phase II trial |common_side_effects=Liver enzyme non-induction, potential increase in chemotherapy concentration, somnolence, constipation, potential liver toxicity |OS_without=Median survival with enzyme-inducing anticonvulsants:..."

New page

{{TreatmentInfo
|drug_name=Valproic Acid/Sodium Valproate (Depakote)
|FDA_approval=Yes (for epilepsy)
|used_for=Investigational use in glioblastoma for its HDAC inhibition properties
|clinical_trial_phase=Retrospective studies and a prospective phase II trial
|common_side_effects=Liver enzyme non-induction, potential increase in chemotherapy concentration, somnolence, constipation, potential liver toxicity
|OS_without=Median survival with enzyme-inducing anticonvulsants: 11 months
|OS_with=Valproic acid users: retrospective study shows median survival of 16.9 months, prospective study shows 29.6 months
|PFS_with=Prospective study shows median PFS of 10.5 months
|usefulness_rating=3
|notes=Valproic acid, an anti-epileptic drug and HDAC inhibitor, has shown potential to improve clinical outcomes in glioblastoma patients. While initial retrospective analyses suggest benefits, particularly in extending median survival and PFS, the results are contested. The debate continues, emphasizing the need for rigorously designed clinical trials to conclusively determine Valproic acid's efficacy in glioblastoma treatment.
|category=Investigational Drugs
|links=
}}